Background and Aim: The coexistence of cerebral venous thrombosis (CVT) and hematological neoplasms is rare. Currently available therapeutic options raise problems concerning the balance of thrombotic and hemorrhagic risks. Our purpose is to characterize a series of cases of CVT and concomitant hematological malignancy, focusing on predisposing factors and treatment strategies. Methods: We performed a descriptive retrospective analysis of the cases of CVT and hematological neoplasms diagnosed in a tertiary center from 2006 to 2015. Results: From the 111 CVT cases diagnosed, only 7 coexisted with hematological malignancy (lymphoma, leukemia, multiple myeloma, and myelodysplastic syndromes). These included 4 women; median age was 44 years old. Median follow-up time was 72 days. The hematological condition was already known in 5 cases. Besides malignancy, we identified other prothrombotic conditions in all cases. Several anticoagulant strategies were used during the acute phase, after which 5 patients remained on warfarin indefinitely. One patient died due to cerebral hemorrhage during the acute phase. In the remaining 6 patients, there was no recurrence of CVT or other complications of anticoagulation. Conclusions: Although these results reiterate the role of hematological malignancy as predisposing factor to CVT, in all cases other factors contributed to CVT etiology, potentiating the risk. We report 1 death directly attributable to a fatal hemorrhagic complication of anticoagulation, evidencing the delicate balance of thrombotic and hemorrhagic risk. Nevertheless, most patients benefited of long-term anticoagulation, which proved a reasonable option. A multidisciplinary approach is paramount in making decisions regarding the time and type of anticoagulation.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Stroke and Cerebrovascular Diseases
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Dural sinus thrombosis owing to polycythaemia vera in a 12-year-old girl.Paediatr Int Child Health. 2012; 32: 167-170
- Dural sinus thrombosis in essential thrombocythemia.Am J Case Rep. 2003; 4: 212-213
- Cerebral venous sinus thrombosis as the first manifestation of JAK2 V617F-positive essential thrombocythemia.Chin Med J (Engl). 2018; 131: 748
- Dural sinus thrombosis in children with acute lymphoblastic leukemia.JAMA. 1981; 246: 2837-2839
- Cerebral sinus venous thrombosis during childhood acute lymphoblastic leukemia therapy: risk factors and management.Pediatr Blood Cancer. 2017; 64: e26694
- Thrombosis and acute lymphoblastic leukaemia.Br J Haematol. 2007; 138: 430-445
- Cerebral dural sinus thrombosis in acute lymphoblastic leukemia with early diagnosis by fast fluid-attenuated inversion recovery (FLAIR) MR image: a case report and review of the literature.Ann Hematol. 2000; 79: 90-94
- Cerebral venous sinus thrombosis associated with essential thrombocytosis in a pediatric patient.J Pediatr Hematol Oncol. 2007; 29: 156-159
- Thrombosis of the cerebral veins and sinuses.N Engl J Med. 2005; 352: 1791-1798
- European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis—endorsed by the European Academy of Neurology.Eur Stroke J. 2017; 2: 195-221
- Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2011; 42: 1158-1192
- Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis.Circulation. 2010; 121: 2740-2746
- Cerebral venous thrombosis: an update.Curr Neurol Neurosci Rep. 2019; 19: 74
Published online: February 11, 2020
Accepted: January 18, 2020
Received in revised form: December 16, 2019
Received: September 30, 2019
© 2020 Elsevier Inc. All rights reserved.